The US Food and Drug Administration (FDA) recently approved pirtobrutinib for people with previously untreated chronic ...

MUMBAI: When Bhavika, 27, returns from work late at night, she doesn’t walk straight to her building. Instead, she phones her brother and asks him to meet her at the gate. “This is how unsafe it has ...

Fugitive diamond businessman Mehul Choksi has dropped his multimillion-pound damages claim against the Indian govt ...

The approval allows Jaypirca to be used as a first-line treatment for eligible patients. Jaypirca is the first and only FDA-approved non-covalent Bruton tyrosine kinase (BTK) inhibitor and is designed ...

“A new development in CLL treatment: Pirtobrutinib moves into the frontline. On October 2, 2026, the US FDA approved ...

ETCFO.com brings latest vijay mallya news, views and updates from all top sources for the Indian CFO industry.

Eli Lilly and Company (NYSE: LLY) announced that the U.S. Food and Drug Administration has approved an expanded indication for Jaypirca (pirtobrutinib) to treat adult patients with ...

The FDA has approved pirtobrutinib (Jaypirca) monotherapy as a treatment for adults with previously untreated chronic ...

The Food and Drug Administration (FDA) has approved Jaypirca® (pirtobrutinib) for the treatment of adult patients with previously untreated chronic ...

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton ...

Eli Lilly’s Jaypirca, the first noncovalent BTK inhibitor, has won FDA approval for the first-line treatment of chronic ...

FDA expands pirtobrutinib into first-line CLL/SLL for adults without 17p deletion, delivering major PFS gains versus ...